FDA approves ONC201 (DORDAVIPRONE, NOW MODEYSO™) for recurrent H3 K27M-MUTANT Diffuse Midline Glioma

Mar 23

Written By Jeannine Gallagher

Jeannine Gallagher

PNOC FOUNDATION LAUNCHES "LOSE NO CHILD" CAMPAIGN

PNOC FOUNDATION LAUNCHES $50 MILLION "LOSE NO CHILD" CAMPAIGN TO TRANSFORM THE FUTURE OF TREATMENT FOR KIDS WITH BRAIN CANCER